Assessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1

Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1

The 7K SomaScan Assay v4.1 is capable of measuring 7,288 human proteins. In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates.(1) Included in the study design were inter-plate technical duplicates from 102 human subjects, which allowed them to characterize different normalization procedures, evaluate assay variability by multiple analytical approaches, present signal-over-background metrics, and discuss potential specificity issues.

By providing detailed performance assessments on this wide range of technical aspects, the presenters aim for this work to serve as a valuable resource for the growing community of SomaScan users.

Topics covered:

  • A comparative analysis of different normalization strategies
  • An analysis of performance across 7,288 SOMAmers® targeting human proteins
  • A discussion of sensitivity and specificity of the assay

Profile image of Julian Candia, PhD

Julián Candia, PhD

Staff Scientist
Longitudinal Studies Section
Translational Gerontology Branch
National Institute on Aging
National Institutes of Health

Image of Dr Keenan Walker

Keenan Walker, PhD

Investigator, National Institute on Aging Intramural Research Program
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND) unit

Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1

A presentation by Julián Candia, PhD, and Keenan Walker, PhD


  1. Candia J, Daya GN, Tanaka T, Ferrucci L, Walker KA. Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci Rep. 2022 Oct 13;12(1):17147. doi: 10.1038/s41598-022-22116-0. PMID: 36229504; PMCID: PMC9561184.

Share with colleagues

More webinars

WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn more

WebinarProteomics for precision neuroscience: the power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.

Learn more